Fiscal period ending 2025-12-31 versus 2024-12-31
— view filing on EDGAR →
Pricing pressure from multiple concurrent regulatory actions — OB3, MFN Executive Order, Colorado PDAB, and Medicare price-setting on Otezla — represents the most consequential shift, with quantified near-term revenue impacts on flagship products including ENBREL and Otezla. Supply chain and cybersecurity risks also escalated materially, with newly named single-source supplier vulnerabilities in an active conflict zone and a freshly disclosed comprehensive cyber threat framework citing real 2025 incidents. Taken together, the risk profile has broadened and deepened across three distinct themes with no offsetting easings.
2 company-specific
· 2 common-mode
Company-specific changes
Revised
New material regulatory developments: OB3 enacted July 2025 affecting Medicare/Medicaid; MFN Executive Order and July 2025 letter requiring pricing concessions; Colorado PDAB set ENBREL UPL substantially below cost effective Jan 2027; Otezla now subject to Medicare price setting effective Jan 2027; Washington PDAB reviewing ENBREL. Company announced December 2025 acceptance of MFN pricing terms. These represent concrete, adverse policy changes with quantified near-term impacts on major products.
RISKS RELATED TO GOVERNMENT REGULATIONS AND THIRD-PARTY POLICIES Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement…
Revised
Substantially expanded disclosure of supply chain risks, including new specific examples (Horizon CMOs, TEPEZZA/KRYSTEXXA single-source suppliers in Israel affected by Middle East conflict), PFAS regulatory threats, and tariff impacts. Risk escalated in detail and severity.
RISKS RELATED TO OPERATIONS We perform a substantial majority of our commercial manufacturing activities at our facility in the U.S. territory of Puerto Rico and a substantial majority of our…
Also disclosed — common-mode (AI cybersecurity escalation, AI regulatory compliance)
AI cybersecurity escalation
New
Newly disclosed comprehensive cybersecurity risk factor covering AI vulnerabilities, third-party breaches, ransomware threats, and regulatory compliance obligations. Includes specific incidents (2025 fraudulent hiring, Change Healthcare disruption) and escalated threat landscape.
RISKS RELATED TO ECONOMIC CONDITIONS AND OPERATING A GLOBAL BUSINESS Our efforts to collaborate with or acquire other companies, products, or technology, and to integrate the operations of companies…
AI regulatory compliance
Revised
New disclosure of USPTO staffing reductions and potential delays to patent examination and enforcement, escalating IP protection risk in early 2025.
RISKS RELATED TO COMPETITION Our products face substantial competition and our product candidates are also likely to face substantial competition. We operate in a highly competitive environment. See…